The latter was present in 8 patients accounting for 2.5%.29 Two studies done in Karachi, Pakistan, showed proportions of CML patients harboring JAK2 V617F mutation as high as 26.7% and 44%.30,31. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.